KRAS mutation + STK11 mutation + KEAP1 mutation
|
NSCLC
|
KRAS mutation + STK11 mutation + KEAP1 mutation
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
KRAS mutation + STK11 mutation + KEAP1 mutation
|
NSCLC
|
KRAS mutation + STK11 mutation + KEAP1 mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|